2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy
J Herrstedt, F Roila, D Warr, L Celio, RM Navari… - Supportive Care in …, 2017 - Springer
Purpose This review summarizes the recommendations for the prophylaxis of nausea and
vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes …
vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes …
Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data
M Aapro, F Scotté, Y Escobar, L Celio, R Berman… - The …, 2021 - academic.oup.com
Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting
control in most patients undergoing chemotherapy. Multinational Association of Supportive …
control in most patients undergoing chemotherapy. Multinational Association of Supportive …
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients …
PJ Hesketh, M Aapro, JC Street, AD Carides - Supportive Care in Cancer, 2010 - Springer
Goals of work Certain patient and treatment characteristics are predictive of chemotherapy-
induced nausea and vomiting (CINV). Objectives of this analysis were:(1) confirm the …
induced nausea and vomiting (CINV). Objectives of this analysis were:(1) confirm the …
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey
P Dielenseger, S Börjeson, C Vidall, A Young… - Supportive Care in …, 2019 - Springer
Introduction Preventing CINV is possible when guideline-recommended antiemetics are
used. Because oncology nurses play a critical role in risk assessment and management of …
used. Because oncology nurses play a critical role in risk assessment and management of …
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - The …, 2015 - academic.oup.com
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
[HTML][HTML] Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a …
J Nishimura, T Satoh, M Fukunaga, H Takemoto… - European Journal of …, 2015 - Elsevier
Introduction The oral neurokinin-1 antagonist aprepitant is recommended in several
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly …
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy
F Roila, D Warr, PJ Hesketh, R Gralla… - Supportive Care in …, 2017 - Springer
Purpose An update of the recommendations for the prophylaxis of acute and delayed
emesis induced by moderately emetogenic chemotherapy published after the last …
emesis induced by moderately emetogenic chemotherapy published after the last …
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …
S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor …
BL Rapoport, K Jordan, JA Boice, A Taylor… - Supportive Care in …, 2010 - Springer
Purpose Aprepitant was shown previously to be effective for prevention of chemotherapy-
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt, R de Wit… - Supportive Care in …, 2006 - Springer
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …